Metabolic Syndrome in Women: The Five Numbers, Why They Climb After Babies and Menopause, and What GLP-1s Change

What are the five criteria for metabolic syndrome in women?

Metabolic syndrome means any three of five: a waist over 35 inches, triglycerides over 150 mg/dL, HDL cholesterol under 50 mg/dL, blood pressure of 130/85 or higher, and fasting glucose of 100 mg/dL or higher. Taking blood pressure or diabetes medication counts as meeting that line. About a third of American women qualify.

This is the page our name promises: the five numbers, why women's numbers move at the two biggest hormonal turns of adult life, and what the GLP-1 trials did to each one.

The five numbers, with the women's cut-offs

Several groups used to define the syndrome differently. In 2009, the major heart, diabetes and obesity bodies agreed a shared version. Three abnormal findings out of five qualify, no single one is required, and waist cut points can follow national standards¹. In the United States, the National Heart, Lung, and Blood Institute uses these cut-offs², and national survey work also counts treated blood pressure and treated glucose³:

Two things in that table are specific to women. The HDL line sits higher for women (50, against 40 for men), and the waist line sits lower (35 inches, against 40)². A woman can be "normal" on a man's sheet and meet the definition on her own.

Why bother with a syndrome at all, rather than five separate problems? The 2009 statement's answer is that these risk factors for heart disease and type 2 diabetes occur together more often than chance alone would explain¹. Three of them at once is a pattern, not a coincidence.

How common it is in women

Using national survey data from 2011 to 2016, researchers estimated that 34.3% of American women had metabolic syndrome, statistically no different from men. Over those five years the share among women rose significantly, from 31.7% to 36.6%. It also rose in adults aged 20 to 39, from 16.2% to 21.3%³. That age band is when most of us have our children.

Most women do not think of themselves this way. In the American Heart Association's 2019 national survey of US women, only 44% knew heart disease is the leading cause of death in women, down from 65% a decade earlier. Awareness fell most among younger women, the group in whom prevention may work best⁴.

Why it climbs after pregnancy and menopause

After a complicated pregnancy. Gestational diabetes is the clearest signal. A meta-analysis of 23 studies found women with a history of it had 3.45 times the odds of developing metabolic syndrome. The odds were higher still when they also carried more weight⁵. If you had it, the fasting-glucose line in the table is the one to watch, and our prediabetes and GLP-1s feature covers the postpartum screening schedule most of us miss.

Through menopause. The Study of Women's Health Across the Nation followed 949 women without the syndrome through menopause. By their final period, 13.7% had developed it. The odds rose 45% for each year of perimenopause and 24% for each year after. The shift was tied to the hormone balance tipping toward testosterone, independent of aging itself⁶.

Women in a 2023 qualitative study of the menopause transition described it as a major life event that came with weight gain and frustrating body changes. Many said they had raised it with clinicians and were disappointed in the support they got⁷. One participant's words became the paper's title: "Weight loss is my goal and being healthy is my goal… I can get over the hot flashes."⁷ Our piece on perimenopause, appetite and GLP-1s picks up from there.

What the GLP-1 trials changed, criterion by criterion

Neither Wegovy nor Zepbound is approved for metabolic syndrome. But both labels report what happened to each component in their main weight trial, in adults without diabetes, against placebo, with lifestyle counseling in every arm^8,9:

Read the table across, and every criterion moved in the right direction on both drugs. The biggest changes were in waist and triglycerides, the smallest in HDL. For glucose, the A1c drop looks small because most participants started near normal. Among those who started with prediabetes, 84.1% on semaglutide in STEP 1 had normal glucose at 68 weeks, against 47.8% on placebo¹⁰.

Two cautions. These are averages: a woman who starts with a 34-inch waist cannot lose a criterion she never met. And the improvements depend on staying on the drug. In STEP 4, the cardiometabolic gains held with continued semaglutide and worsened after people switched to placebo¹¹.

The hard outcome sits in a different trial. SELECT enrolled 17,604 adults with existing heart disease and overweight or obesity, but no diabetes. Over about 40 months, heart attack, stroke or cardiovascular death occurred in 6.5% on semaglutide and 8.0% on placebo, a 20% relative reduction¹². Who was in that room, and how few women, is its own story. We tell it in the heart benefit and who was in the room.

What to ask for at your next physical

Most of the five numbers come from a standard visit: a blood pressure reading, a fasting lipid panel and a fasting glucose or A1c. The waist you can measure at home, at the top of the hip bones, breathing out. Write the five down next to the cut-offs in the table above and count. If you hit three, ask directly whether you have metabolic syndrome, because the label changes the conversation. Then ask which number is the easiest one to move first.

If a GLP-1 is part of that plan, our board for women and board for mothers compare the programs. If insurance is the question, start with the coverage board.